Don’t Delay With Delta: Best Practices and Calls to Action in HDV

Download All
In this series of concise, engaging Medical Minutes and podcasts, hear from international experts on the global burden of HDV, risk factors and screening recommendations, new treatment options and current management recommendations, and the evolving therapeutic landscape. Gain patient perspectives to better understand the impact of disease and delays in diagnosis.
Paul Y. Kwo, MD
Norah Terrault Headshot
Norah Terrault, MD, MPH
Heiner Wedemeyer, MD
person default
Cihan Yurdaydin, MD


To link patients with hepatitis delta virus to care, we first must be able to identify them.

person default Cihan Yurdaydin, MD Released: March 8, 2022

Emerging treatment options for hepatitis delta virus are promising, but we still have more questions than answers regarding the optimal use of these agents around the globe.

Heiner Wedemeyer, MD Released: March 23, 2022

My thinking about HDV testing recommendations has shifted in recent years. Here’s why.

Norah Terrault Headshot Norah Terrault, MD, MPH Released: May 18, 2022

Our current treatment option for hepatitis delta virus is pegylated interferon alfa, which does not have robust efficacy data and is not always well tolerated—but many novel investigational agents are being studied to provide more efficacious, better tolerated therapies

Paul Y. Kwo, MD Released: August 2, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings